Mario Ostrowski




My current research interests focus on the immunopathogenesis of Human Immunodeficiency Virus (HIV) /Acquired Immune Deficiency Syndrome (AIDS) and Hepatitis C Virus (HCV) and other virus infections including SARS-CoV-2. We are interested in understanding why chronic virus infections persist in the host. Current work is divided along the following lines:

  1. Examination of T cell immune response to HIV and HCV infection.
  2. Therapeutic and preventive vaccine strategies
  3. immunomodulation during virus infections

Recent Publications

  1. Grundy, EE, Shaw, LC, Wang, L, Powell, DJ, Ostrowski, M, Jones, RB et al.. Limited Immunogenicity of an HLA-A*03:01-restricted Epitope of Erv-k-env in Non-hiv-1 Settings: Implications for Adoptive Cell Therapy in Cancer. Res Sq. 2024; :. doi: 10.21203/ PubMed PMID:38854052 PubMed Central PMC11160923.
  2. Costiniuk, CT, Lee, T, Singer, J, Galipeau, Y, Arnold, C, Langlois, MA et al.. Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study. Vaccines (Basel). 2024;12 (5):. doi: 10.3390/vaccines12050447. PubMed PMID:38793698 PubMed Central PMC11125718.
  3. Budylowski, P, Chau, SLL, Banerjee, A, Guvenc, F, Samson, R, Hu, Q et al.. A Significant Contribution of the Classical Pathway of Complement in SARS-CoV-2 Neutralization of Convalescent and Vaccinee Sera. J Immunol. 2024;212 (12):1922-1931. doi: 10.4049/jimmunol.2300320. PubMed PMID:38683124 .
  4. Reiter, L, Greffrath, J, Zidel, B, Ostrowski, M, Gommerman, J, Madhi, SA et al.. Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study. Sci Rep. 2024;14 (1):5365. doi: 10.1038/s41598-024-55320-1. PubMed PMID:38438427 PubMed Central PMC10912344.
  5. Tan, DHS, Pico Espinosa, O, Matelski, J, Khera, SS, Qamar, A, Persaud, R et al.. Longitudinal Analysis of Mpox Virus DNA Detectability From Multiple Specimen Types During Acute Illness: A Cohort Study. Open Forum Infect Dis. 2024;11 (2):ofae073. doi: 10.1093/ofid/ofae073. PubMed PMID:38390463 PubMed Central PMC10883290.
  6. Huang, YH, Zhu, C, Kondo, Y, Anderson, AC, Gandhi, A, Russell, A et al.. Author Correction: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2024;626 (8001):E19. doi: 10.1038/s41586-024-07164-y. PubMed PMID:38336833 .
  7. Nantel, S, Sheikh-Mohamed, S, Chao, GYC, Kurtesi, A, Hu, Q, Wood, H et al.. Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity. Mucosal Immunol. 2024;17 (2):201-210. doi: 10.1016/j.mucimm.2024.01.004. PubMed PMID:38278415 .
  8. Matveev, VA, Mihelic, EZ, Benko, E, Budylowski, P, Grocott, S, Lee, T et al.. Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV. iScience. 2023;26 (10):107915. doi: 10.1016/j.isci.2023.107915. PubMed PMID:37790281 PubMed Central PMC10542941.
  9. Costiniuk, CT, Singer, J, Lee, T, Galipeau, Y, McCluskie, PS, Arnold, C et al.. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada. AIDS. 2023;37 (12):F25-F35. doi: 10.1097/QAD.0000000000003680. PubMed PMID:37534695 PubMed Central PMC10481923.
  10. Matveev, VA, Mihelic, EZ, Benko, E, Budylowski, P, Grocott, S, Lee, T et al.. Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV. bioRxiv. 2023; :. doi: 10.1101/2023.06.14.544834. PubMed PMID:37502977 PubMed Central PMC10370192.
Search PubMed

Affiliations & Other Activities

  • Infectious Disease Consultant, St. Michael’s Hospital
  • Professor, Department of Medicine, Immunology, Lab Medicine, Pathobiology, University of Toronto